Drugmakers have been wooing small players in the skin-treatment field, and just last month, Valeant Pharmaceuticals announced that it had agreed to buy Obagi Medical for $345 million. But now, Merz Pharma has trumped that bid.
Valeant Pharmaceuticals is socking another $350 million or so into the dermatology business. It's picking up the skin-care company Obagi Medical Products for $344 million in a $19.75-per-share buyout--just a few months after closing its $2.6 billion deal for Medicis Pharmaceutical.
Miami-based Brickell Biotech grabbed $7 million in a new venture round led by a South Korean cosmetics company to back its work on new chemical entities for dermatology.
Is 2013 the year that Sun Pharmaceutical Industries makes a European deal? Chairman Israel Makov tells Bloomberg that the Indian drugmaker is, in fact, scouting the region for deals.
Perrigo has further solidified its position in topical dermatology drugs, one of the areas in which prices have been escalating of late.
The end of the year M&A action seems to be on. Botox maker Allergan has agreed to pay $350 million to pick up skin products company, SkinMedica, Bloomberg reports.
India-based Sun Pharmaceutical is buying U.S. drugmaker DUSA Pharmaceuticals for about $230 million, or $8 per share, a 38% premium to yesterday's closing price.
Venture investors have recommitted to a familiar team of dermatology drug developers. The team, which sold Vicept Therapeutics to Botox maker Allergan ($AGN) last year, has formed Aclaris Therapeutics and raised $21 million in a Series A round to fund development of new dermatology therapies.
Biotech billionaire RJ Kirk has hitched another therapeutic developer to his synthetic biology wagon at Intrexon. This time it's Fibrocell Science, an Exton, PA-based developer with a personalized cell therapy for "aesthetic dermatology" on the market.
Just over a year ago, word was that Valeant Pharmaceuticals wanted to buy Medicis Pharmaceuticals. Apparently the time wasn't really right until now. Valeant has agreed to buy Medicis for $2.6 billion, or $44 per share.